Your browser doesn't support javascript.
loading
Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAFV600E inhibitors.
Kim, TaeWon; Havighurst, Thomas; Kim, KyungMann; Albertini, Mark; Xu, Yaohui G; Spiegelman, Vladimir S.
Affiliation
  • Kim T; Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
  • Havighurst T; Molecular and Environmental Toxicology Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
  • Kim K; Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
  • Albertini M; Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
  • Xu YG; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
  • Spiegelman VS; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Mol Carcinog ; 57(5): 678-683, 2018 05.
Article in En | MEDLINE | ID: mdl-29369405
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA-Binding Proteins / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Vemurafenib / Melanoma Limits: Humans Language: En Journal: Mol Carcinog Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: RNA-Binding Proteins / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Vemurafenib / Melanoma Limits: Humans Language: En Journal: Mol Carcinog Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2018 Type: Article